Imatinib Unknown Status Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00744081Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)